ArticleAmerican journal of ophthalmology case reports2025
Long-term follow-up and treatment of lamellar hole-associated epiretinal proliferation presenting with exudative perivascular anomalous complex.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a patient with lamellar hole-associated epiretinal proliferation (LHEP), presenting with exudative perifoveal vascular anomalous complex (ePVAC), who was initially treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF), aflibercept 2 mg followed by dexamethasone intravitreal implant 0.7 mg. Observations: A complete ophthalmologic examination was performed on a 74-year-old woman who was referred for unilateral blurred vision. The patient was in good general health with no history of diabetes, hypertension, or blood dyscrasias and was followed up with swept source optical coherence tomography (SS-OCT). The patient was followed from September 2019 to March 2024.Multimodal imaging of the left eye showed epiretinal proliferation (ERP) with lamellar hole (LM) formation associated with perifoveal isolated large aneurysmal change, accompanied by small hemorrhage, intraretinal exudation and small hard exudate accumulations.The patient received three monthly intravitreal injections as a loading dose (LD), followed by treat and extend regimen. Four weeks post LD the mean central retinal thickness (CMT) decreased from 467 to 288 μm, LHEP cystoid spaces were reduced, and best corrected visual acuity (BCVA) improved from 20/120 to 20/60. Treatment continued with extended intervals. After 11 injections there was a follow-up loss at 18 weeks with deterioration of BCVA.After a total of 18 aflibercept injections it was decided to switch to dexamethasone intravitreal implant. At three months there was anatomical improvement and the ePVAC lesions almost disappeared. At 14 weeks after the second implant, OCT confirmed further anatomical improvement and involution of the PVAC lesions. At 10 weeks after the third dexamethasone intravitreal implant there was a deterioration due to the progression of cataract and BCVA had dropped to 20/120. The intraocular pressure was between normal limits during the follow-up period. Conclusions and importance: Anti-VEGF therapy is less effective than dexamethasone intravitreal implant with a treatment interval greater than 12 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.